Precancer atlas to drive precision prevention trials

Cancer Research

Volumn 77, Issue 7, 2017, Pages 1510-1541

  Spira, Avrum ^a   Yurgelun, Matthew B ^b   Alexandrov, Ludmil ^c   Rao, Anjana ^d   Bejar, Rafael ^e   Polyak, Kornelia ^b   Giannakis, Marios ^b   Shilatifard, Ali ^f   Finn, Olivera J ^g   Dhodapkar, Madhav ^h   Kay, Neil E ⁱ   Braggio, Esteban ⁱ   Vilar, Eduardo ^j   Mazzilli, Sarah A ^a   Rebbeck, Timothy R ^k   Garber, Judy E ^b   Velculescu, Victor E ^l   Disis, Mary L ^m   Wallace, Douglas C ^n,o   Lippman, Scott M ^e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CENTER FOR NONLINEAR STUDIES   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h YALE CANCER CENTER   (United States)

ⁱ MAYO CLINIC HOSPITAL   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BUTYRIC ACID; CANCER VACCINE; CELECOXIB; DENOSUMAB; ERLOTINIB; INTERLEUKIN 17 ANTIBODY; LETROZOLE; METFORMIN; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; SULINDAC; TAMOXIFEN; ULIPRISTAL; WART VIRUS VACCINE;

ADJUVANT THERAPY; AGING; ANTIPROLIFERATIVE ACTIVITY; AUTOPHAGY; BARRETT ESOPHAGUS; BIOINFORMATICS; BREAST CANCER; BREAST SURGERY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLON RESECTION; COLORECTAL CANCER; DRUG RESISTANCE; DRUG SENSITIVITY; DUODENUM CANCER; EPIGENETICS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FAMILIAL COLON POLYPOSIS; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITARY TUMOR; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MISMATCH REPAIR; MITOCHONDRIAL RESPIRATION; NEXT GENERATION SEQUENCING; NONHUMAN; OBESITY; ONCOGENE; PANCREAS TUMOR; PERSONALIZED MEDICINE; POSTMENOPAUSE OSTEOPOROSIS; PRECANCER; REVIEW; SINGLE CELL ANALYSIS; ANIMAL; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MITOCHONDRION; NEOPLASMS; PHYSIOLOGY; PRECANCEROUS CONDITIONS; TUMOR MICROENVIRONMENT;

ANIMALS; CANCER VACCINES; CELLULAR MICROENVIRONMENT; DNA, MITOCHONDRIAL; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MITOCHONDRIA; NEOPLASMS; PRECANCEROUS CONDITIONS; PRECISION MEDICINE; SINGLE-CELL ANALYSIS;

EID: 85017347096     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2346     Document Type: Review

References (412)

1. Hudson KL, Collins FS. The 21st Century Cures Act-A View from the NIH. N Engl J Med 2017;376:111-13.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
3. Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, et al. Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res 2016;9:417-27.
4. Blackburn EH. Cancer interception. Cancer Prev Res 2011;4:787-92.
5. Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, et al. Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A 2016;113:10750-8.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
7. Rahman N. Realizing the promise of cancer predisposition genes. Nature 2014;505:302-8.
8. To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, et al. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res 2014;7:698-707.
9. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016;22:813-20.
10. Le DT, Uram JN,WangH, Bartlett BR, KemberlingH, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
11. Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 2016;315:1266-75.
12. Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 2016;34:1460-8.
13. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 2017 Jan 30:[Epub ahead of print].
14. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 2015;373:2336-46.
15. Joost P, Therkildsen C, Dominguez-Valentin M, Jönsson M, Nilbert M. Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 2015;86:1212-7.
16. Schaefer MH, Serrano L. Cell type-specific properties and environment shape tissue specificity of cancer genes. Sci Rep 2016;6:20707.
17. SedicM, Skibinski A, Brown N, GallardoM, Mulligan P, Martinez P, et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 2015;6:7505.
18. Benitez-Buelga C, Vaclova T, Ferreira S, Urioste M, Inglada-Perez L, Soberon N, et al. Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers. Oncotarget 2016; 7:25815-25.
19. Uziel O, Yerushalmi R, Zuriano L, Naser S, Beery E, Nordenberg J, et al. BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo. Oncotarget 2016;7:2433-54.
20. Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, et al. The sex hormone system in carriers of BRCA1/2 mutations: a casecontrol study. Lancet Oncol 2013;14:1226-32.
21. Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 2014;5:5496.
22. Savage KI,Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, et al. BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res 2014;74:2773-84.
23. Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun 2013;4:2578.
24. Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, et al. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations. Oncotarget 2016;7:45317-30.
25. Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, et al. Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proc Natl Acad Sci U S A 2014;111: 4472-7.
26. Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, et al. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res 2010; 70:2538-47.
27. Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad SciUS A 2007;104:5794-9.
28. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 201547:1294-303.
29. Cuyas E, Fernandez-Arroyo S, Alarcon T, Lupu R, Joven J,Menendez JA. Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. Oncotarget 2016;7:52974-92.
30. Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov 2017;7:72-85.
31. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31:2942-62.
32. Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-Analysis. Breast Cancer 2015;22:327-34.
33. Alothman SJ, Wang W, Goerlitz DS, Islam M, Zhong X, Kishore A, et al. Responsiveness of Brca1 and Trp53 deficiency induced mammary preneoplasia to selective estrogen modulators versus an aromatase inhibitor in Mus musculus. Cancer Prev Res in press.
34. Jeong JH, Jo A, Park P, Lee H, Lee HO. Brca2 deficiency leads to T cell loss and immune dysfunction. Mol Cells 2015;38:251-8.
35. Dabydeen SA, Kang K, Diaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, et al. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-Associated gene signature linked to tamoxifen resistance. Carcinogenesis 2015;36:122-32.
36. Nolan E, Vaillant F, Branstetter D, Pal B,Giner G, Whitehead L, et al.RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 2016;22:933-9.
37. Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A,Wirnsberger G, Novatchkova M, et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res 2016;26:761-74.
38. Gross K, Wronski A, Skibinski A, Phillips S, Kuperwasser C. Cell fate decisions during breast cancer development. J Dev Biol 2016;4:4.
39. Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, et al. Persistent activation ofNF-kappaB in BRCA1-deficientmammary progenitors drives aberrant proliferation and accumulation of DNA damage. Cell Stem Cell 2016;19:52-65.
40. Phillips S, Prat A, Sedic M, Proia T, Wronski A, Mazumdar S, et al. Cellstate transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Rep 2014;2:633-47.
41. Melchor L, Molyneux G, Mackay A, Magnay FA, Atienza M, Kendrick H, et al. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol 2014;233:124-37.
42. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 2012;72:2879-88.
43. Nolan E, Lindeman GJ, Visvader JE. Out-RANKing BRCA1 in mutation carriers. Cancer Res 2017;77:595-600.
44. Galluzzi L, Buque A, Kroemer G. Prevention of breast cancer by RANKL/RANK blockade. Cell Res 2016;26:751-2.
45. Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, et al. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-kappaB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine 2015;2:1331-9.
46. Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016;2:1434-40.
47. Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2017;109.
48. Kais Z, Rondinelli B, Holmes A, O'Leary C, Kozono D, D'Andrea AD, et al. FANCD2 maintains fork stability in BRCA1/2-deficient tumors and promotes alternative end-joining DNA repair. Cell Rep 2016;15: 2488-99.
49. Longerich S, Li J, Xiong Y, Sung P, Kupfer GM. Stress and DNA repair biology of the Fanconi anemia pathway. Blood 2014;124:2812-9.
50. Sumpter R Jr, Sirasanagandla S, Fernandez AF, Wei Y, Dong X, Franco L, et al. Fanconi anemia proteins function inmitophagy and immunity. Cell 2016;165:867-81.
51. Belcheva A, Irrazabal T, Robertson SJ, Streutker C, Maughan H, Rubino S, et al. Gut microbial metabolismdrives transformation ofMSH2-deficient colon epithelial cells. Cell 2014;158:288-99.
52. Montrose DC, Zhou XK, McNally EM, Sue E, Yantiss RK, Gross SS, et al. Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden. Cancer Prev Res 2016;9:721-31.
53. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-15.
54. Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, et al. Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res 2016;76:2115-24.
55. Levy J, Cacheux W, Bara MA, L'Hermitte A, Lepage P, Fraudeau M, et al. Intestinal inhibition of Atg7 prevents tumour initiation through amicrobiome-influenced immune response and suppresses tumour growth. Nat Cell Biol 2015;17:1062-73.
56. Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European Expert Centers. J Clin Oncol 2016;34:2010-9.
57. Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 2015;121:4382-8.
58. Beatty PL, van der Geest R, Hashash JG, Kimura T, Gutkin D, Brand RE, et al. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunol Immunother 2016; 65:771-8.
59. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30:2654-63.
60. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001;98:13255-60.
61. Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm G, Yuan Y, et al. Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters. Clin Cancer Res 2017 Mar 6: [Epub ahead of print].
62. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008;134:988-97.
63. Borras E, Pande M, Chang K, Cuddy A, Bannon SA, Mork ME, et al. In Silico systems biology analysis of variants of uncertain significance in Lynch syndrome supports the prioritization of functional molecular validation. Cancer Prev Res in press.
64. Yurgelun MB, Chenevix-Trench G, Lippman SM. Translating germline cancer risk into precision prevention. Cell 2017;168:566-70.
65. Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in lynch syndrome. J Natl Cancer Inst 2015;107:djv170.
66. Oxnard GR, Heng JC, Root EJ, Rainville IR, Sable-Hunt AL, Shane-Carson KP, et al. Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR. J Clin Oncol 33, 2015 (suppl; abstr 1505).
67. Wu X, Wen CP, Ye Y, Tsai M, Wen C, Roth JA, et al. Personalized risk assessment in never, light, and heavy smokers in a prospective cohort in Taiwan. Sci Rep 2016;6:36482.
68. Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun 2015;6:10086.
69. Campbell PJ. Somatic and germline genetics at the JAK2 locus. Nat Genet 2009;41:385-6.
70. Liu W, He L, Ramirez J, Krishnaswamy S, Kanteti R, Wang YC, et al. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res 2011; 71:2423-7.
71. Li Q, Seo JH, Stranger B, McKenna A, Pe'er I, Laframboise T, et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 2013;152:633-41.
72. Carter H, Marty R, HofreeM, Gross A, Jensen J, Fisch KM, et al. Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov 2017 Feb 10.
73. Puzone R, Pfeffer U. SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CAvariants in breast cancers. Eur JHumGenet 2017;25:384-87.
74. Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 2016;30:918-30.
75. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, et al. Genome-wide meta-Analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discov 2016;6:1052-67.
76. Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, et al. The OncoArray Consortium: a network for understanding the genetic architecture of common cancers. Cancer Epidemiol Biomarkers Prev 2017; 26:126-35.
77. Walker LC, Marquart L, Pearson JF, Wiggins GA, O'Mara TA, Parsons MT, et al. Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 2017 Feb 1.
78. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun 2016;7: 11375.
79. He Y, Gorkin DU, Dickel DE, Nery JR, Castanon RG, Lee AY, et al. Improved regulatory element prediction based on tissue-specific local epigenomic signatures. Proc Natl Acad Sci U S A 2017;114: E1633-40.
80. Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet 2016;48:1330-8.
81. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 2014;46:487-91.
82. Wallace DC. Mitochondrial DNA variation in human radiation and disease. Cell 2015;163:33-8.
83. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab 2016;23:27-47.
84. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006;25:4647-62.
85. Arnold RS, Sun Q, Sun CQ, Richards JC, O'Hearn S, Osunkoya AO, et al. An inherited heteroplasmic mutation in mitochondrial gene COI in a patient with prostate cancer alters reactive oxygen, reactive nitrogen and proliferation. Biomed Res Int 2013;2013:239257.
86. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 2005;102:719-24.
87. Canter JA, Kallianpur AR, Parl FF, Millikan RC. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 2005;65:8028-33.
88. Permuth-Wey J, Chen YA, Tsai YY, Chen Z, Qu X, Lancaster JM, et al. Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1131-45.
89. Williams SB, Ye Y, Huang M, Chang DW, Kamat AM, Pu X, et al. Mitochondrial DNA content as risk factor for bladder cancer and its association with mitochondrial DNA Polymorphisms. Cancer Prev Res 2015;8:607-13.
90. Liu VW, Wang Y, Yang HJ, Tsang PC, Ng TY, Wong LC, et al. Mitochondrial DNA variant 16189TC is associated with susceptibility to endometrial cancer. Hum Mutat 2003;22:173-4.
91. Zhai K, Chang L, Zhang Q, Liu B, Wu Y. Mitochondrial C150T polymorphism increases the risk of cervical cancer and HPV infection. Mitochondrion 2011;11:559-63.
92. Zhai K, Chang L, Zhang Q, Liu B, Wu Y. Mitochondrial C150T polymorphism increases the risk of cervical cancer and HPV infection. Mitochondrion 2011;11:559-63.
93. Schroder T, Kucharczyk D, Bar F, Pagel R, Derer S, Jendrek ST, et al. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-Alcoholic steatohepatitis. Mol Metab 2016;5:283-95.
94. Fan W, Waymire KG, Narula N, Li P, Rocher C, Coskun PE, et al. A mouse model ofmitochondrial disease reveals germline selection against severe mtDNA mutations. Science 2008;319:958-62.
95. Gasparre G, Iommarini L, Porcelli AM, Lang M, Ferri GG, Kurelac I, et al. An inherited mitochondrial DNA disruptive mutation shifts to homoplasmy in oncocytic tumor cells. Hum Mutat 2009;30:391-6.
96. Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. Mol Cell 2016;61:667-76.
97. Feeley KP, Bray AW, Westbrook DG, Johnson LW, Kesterson RA, Ballinger SW, et al. Mitochondrial genetics regulate breast cancer tumorigenicity and metastatic potential. Cancer Res 2015; 75:4429-36.
98. Schriner SE, Linford NJ,Martin GM, Treuting P,Ogburn CE, Emond M, et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005;308:1909-11.
99. Goh J, Enns L, Fatemie S, Hopkins H, Morton J, Pettan-Brewer C, et al. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer 2011;11:191.
100. Latorre-Pellicer A, Moreno-Loshuertos R, Lechuga-Vieco AV, Sanchez-Cabo F, Torroja C, Acin-Perez R, et al. Mitochondrial and nuclear DNA matching shapes metabolism and healthy ageing. Nature 2016; 535:561-5.
101. Picard M, Zhang J, Hancock S, Derbeneva O, Golhar R, Golik P, et al. Progressive increase in mtDNA 3243AG heteroplasmy causes abrupt transcriptional reprogramming. Proc Natl Acad Sci U S A 2014;111: E4033-42.
102. Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, et al. Inhibiting mitochondrial respiration prevents cancer in amouse model of Li-Fraumeni syndrome. J Clin Invest 2017;127:132-136.
103. Dong LF, Kovarova J, Bajzikova M. Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNAdeficient cancer cells. eLife 2017;10.7554/eLife.22187.
104. Chen PL, Chen CF, Chen Y, Guo XE, Huang CK, Shew JY, et al. Mitochondrial genome instability resulting from SUV3 haploinsufficiency leads to tumorigenesis and shortened lifespan. Oncogene 2013; 32:1193-201.
105. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014;508:108-12.
106. Dan Dunn J, Alvarez LA, Zhang X, Soldati T. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biol 2015; 6:472-85.
107. Blein S, Bardel C,Danjean V, McGuffog L,Healey S, Barrowdale D, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 2015;17:61.
108. Blein S, Barjhoux L; GENESIS investigators, Damiola F, Dondon MG, Eon-Marchais S, et al. Targeted sequencing of the mitochondrial genome of women at high risk of breast cancer without detectable mutations in BRCA1/2. PLoS One 2015;10:e0136192.
109. Garrett WS. Cancer and the microbiota. Science 2015;348:80-6.
110. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature 2016;535:65-74.
111. Beane J, Campbell JD, Lel J, Vick J, Spira A. Genomic approaches to accelerate cancer interception. Lancet Oncol in press.
112. O'Connell MA, Mannion NM, Keegan LP. The epitranscriptome and innate immunity. PLoS Genet 2015;11:e1005687.
113. Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 2016;30:733-50.
114. Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. Epigenetics in cancer: A hematological perspective. PLoS Genet 2016;12: e1006193.
115. Rebbeck TR, Sellers TA. The Fruits of the genomic revolution. Cancer Epidemiol Biomarkers Prev in press.
116. Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-Analysis. Lancet Oncol 2016;17:1363-73.
117. Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, et al. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2016; [Epub ahead of print].
118. Fecteau RE, Kong J, Kresak A, Brock W, Song Y, Fujioka H, et al. Association between germline mutation in VSIG10L and familial barrett neoplasia. JAMA Oncol 2016;2:1333-9.
119. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-Analysis. Gastroenterology 2013; 144:799-807.
120. Whiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, Zgaga L, et al. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-Analysis. Hum Mol Genet 2014;23:4729-37.
121. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, et al. Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res 2016;18:22.
122. Hollstein M, Alexandrov LB, Wild CP, Ardin M, Zavadil J. Base changes in tumour DNA have the power to reveal the causes and evolution of cancer. Oncogene 2017;36:158-67.
123. Hoang ML, Kinde I, Tomasetti C, McMahon KW, Rosenquist TA, Grollman AP, et al. Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc Natl Acad Sci U S A 2016;113:9846-51.
124. Imielinski M, Guo G, Meyerson M. Insertions and deletions target lineage-defining genes in human cancers. Cell 2017;168:460-472.
125. Forsberg LA, Rasi C, Pekar G, Davies H, Piotrowski A, Absher D, et al. Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer. Genome Res 2015;25:1521-35.
126. Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015; 348:880-6.
127. Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, et al. Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma: a review of the evidence. Cancer Prev Res 2016;9:713-20.
128. Shi K, Carpenter MA, Banerjee S, Shaban NM, Kurahashi K, Salamango DJ, et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat Struct Mol Biol 2017;24:131-9.
129. Starrett GJ, Luengas EM, McCann JL, Ebrahimi D, Temiz NA, Love RP, et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat Commun 2016; 7:12918.
130. Robles-Espinoza CD, Roberts ND, Chen S, Leacy FP, Alexandrov LB, Pornputtapong N, et al. Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun 2016;7:12064.
131. Zamborszky J, Szikriszt B, Gervai JZ, Pipek O, Poti A, Krzystanek M, et al. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene 2017;36:746-55.
132. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899-905.
133. Alexandrov LB, Nik-Zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun 2015;6:8683.
134. Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, et al. Association of distinct mutational signatures with correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol 2016:[Epub ahead of print].
135. Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 2016;48:1131-41.
136. Smid M, Rodriguez-Gonzalez FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, et al. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun 2016;7:12910.
137. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016;7:13587-98.
138. Rashid M, Fischer A, Wilson CH, Tiffen J, Rust AG, Stevens P, et al. Adenoma development in familial adenomatous polyposis andMUTYHassociated polyposis: somatic landscape and driver genes. J Pathol 2016;238:98-108.
139. Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Tiao G, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 2016;48:600-6.
140. McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman SM. Identifying and creating the next generation of community-based cancer prevention studies: summary of a national cancer institute think tank. Cancer Prev Res 2017;10:99-107.
141. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015;373:1618-26.
142. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet 2015;47:1402-7.
143. Podolskiy DI, Lobanov AV, Kryukov GV, Gladyshev VN. Analysis of cancer genomes reveals basic features of human aging and its role in cancer development. Nat Commun 2016;7:12157.
144. Alexandrov LB, Ju YS, Haase K, Van Loo P,Martincorena I, Nik-Zainal S, et al. Mutational signatures associated with tobacco smoking in human cancer. Science 2016;354:618-22.
145. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015;47: 367-72.
146. Kim SY, Jung SH, Kim MS, Baek IP, Lee SH, Kim TM, et al. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget 2015; 6:7597-607.
147. Sakr RA, Schizas M, Carniello JV, Ng CK, Piscuoglio S, Giri D, et al. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Mol Oncol 2016;10:360-70.
148. Hosoda W, Chianchiano P, Griffin JF, Pittman ME, Brosens LA, Noë M, et al. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J Pathol 2017 Feb 11:[Epub ahead of print].
149. Wood HM,Conway C, Daly C, Chalkley R, Berri S, Senguven B, et al. The clonal relationships between pre-cancer and cancer revealed by ultra-deep sequencing. J Pathol 2015;237:296-306.
150. Vogelstein B, Kinzler KW. The path to cancer-three strikes and you're out. N Engl J Med 2015;373:1895-8.
151. Vinayanuwattikun C, Le Calvez-Kelm F, Abedi-Ardekani B, Zaridze D, Mukeria A, Voegele C, et al. Elucidating genomic characteristics of lung cancer progression from in situ to Invasive Adenocarcinoma. Sci Rep 2016;6:31628.
152. Kass EM, Moynahan ME, Jasin M. When genome maintenance goes badly awry. Mol Cell 2016;62:777-87.
153. Ross-Innes CS, Becq J, Warren A, Cheetham RK, Northen H, O'Donovan M, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet 2015;47:1038-46.
154. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet 2015;47:1047-55.
155. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014;46:837-43.
156. Zeng J, Kelbauskas L, Rezaie A, Lee K, Ueberroth B, Gao W, et al. Transcriptional regulation by normal epithelium of premalignant to malignant progression in Barrett's esophagus. Sci Rep 2016;6:35227.
157. Nadatani Y, Huo X, Zhang X, Yu C, Cheng E, Zhang Q, et al. NODlike receptor protein 3 inflammasome priming and activation in Barrett's epithelial cells. Cell Mol Gastroenterol Hepatol 2016;2: 439-53.
158. Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife 2014; 3:e02935.
159. Stewart JB, Alaei-Mahabadi B, Sabarinathan R, Samuelsson T, Gorodkin J, Gustafsson CM, et al. SimultaneousDNAand RNA mapping of somatic mitochondrial mutations across diverse human cancers. PLoS Genet 2015;11:e1005333.
160. Reznik E, Wang Q, La K, Schultz N, Sander C. Mitochondrial respiratory gene expression is suppressed in many cancers. eLife 2017; 6:e21592.
161. Lee S, Han MJ, Lee KS, Back SC, Hwang D, Kim HY, et al. Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia. PLoS One 2012;7:e37571.
162. Nicholson AM, Graham TA, Simpson A, Humphries A, Burch N, Rodriguez-Justo M, et al. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. Gut 2012;61:1380-9.
163. Huhta H, Helminen O, Palomäki S, Kauppila JH, Saarnio J, Lehenkari PP, et al. Intratumoral lactate metabolism in Barrett's esophagus and adenocarcinoma. Oncotarget 2017 Feb 11:[Epub ahead of print].
164. Saini N, Roberts SA, Klimczak LJ, Chan K, Grimm SA, Dai S, et al. The impact of environmental and endogenous damage on somatic mutation load in human skin fibroblasts. PLoS Genet 2016;12:e1006385.
165. Martelotto LG, Baslan T, Kendall J, Geyer FC, Burke KA, Spraggon L, et al. Whole-genome single-cell copy number profiling from formalinfixed paraffin-embedded samples. Nat Med 2017;Feb 6:[Epub ahead of print].
166. Godec J, Tan Y, Liberzon A, Tamayo P, Bhattacharya S, Butte AJ, et al. Compendium of immune signatures Identifies conserved and species-specific biology in response to inflammation. Immunity 2016; 44:194-206.
167. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
168. Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, et al. Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol 2016;34:539-46.
169. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2016;30:355-85.
170. Liou GY, Doppler H, Necela B, Edenfield B, Zhang L, Dawson DW, et al. Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov 2015;5:52-63.
171. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, et al. IL35-Producing B Cells promote the development of pancreatic neoplasia. Cancer Discov 2016;6:247-55.
172. Wörmann SM, Diakopoulos KN, Lesina M, Algül H. The immune network in pancreatic cancer development and progression. Oncogene 2014;33:2956-67.
173. Krogan NJ, Lippman S, Agard DA, Ashworth A, Ideker T. The cancer cell map initiative: defining the hallmark networks of cancer. Mol Cell 2015;58:690-8.
174. Hu D, Shilatifard A. Epigenetics of hematopoiesis and hematological malignancies. Genes Dev 2016;30:2021-41.
175. Teschendorff AE, Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, et al. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat Commun 2016;7:10478.
176. Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer 2015;18:65-76.
177. Wali RK, Momi N, Dela Cruz M, Calderwood AH, Stypula-Cyrus Y, Almassalha L, et al. Higher order chromatinmodulator cohesin SA1 is an early biomarker for colon carcinogenesis: race-specific implications. Cancer Prev Res 2016;9:844-854.
178. Yang Z, Wong A, Kuh D, Paul DS, Rakyan VK, Leslie RD, et al. Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol 2016;17:205.
179. Siegmund KD, Marjoram P, Woo YJ, Tavare S, Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci U S A 2009; 106:4828-33.
180. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012;44: 1179-81.
181. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDHmutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-8.
182. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, et al. MDSassociated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015; 126:2355-61.
183. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 2015;372:601-12.
184. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38.
185. Blaschke K, Ebata KT, Karimi MM, Zepeda-Martinez JA, Goyal P, Mahapatra S, et al. VitaminCinduces Tet-dependentDNAdemethylation and a blastocyst-like state in ES cells. Nature 2013;500:222-6.
186. Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015;525:389-93.
187. Yue X, Trifari S, Aijo T, Tsagaratou A, Pastor WA, Zepeda-Martinez JA, et al. Control of Foxp3 stability through modulation of TET activity. J Exp Med 2016;213:377-97.
188. Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z, et al. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget 2016;7:72381-94.
189. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, et al. The Genomic Landscape and Clinical Relevance of A-to-I RNA editing in human cancers. Cancer Cell 2015;28:515-28.
190. Wulff BE, Nishikura K. Modulation of microRNA expression and function by ADARs. Curr Top Microbiol Immunol 2012;353:91-109.
191. Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 2013;19:209-16.
192. Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2013;110:1041-6.
193. Qi L, Chan TH, Tenen DG, Chen L. RNA editome imbalance in hepatocellular carcinoma. Cancer Res 2014;74:1301-6.
194. Chen Y, Wang H, Lin W, Shuai P. ADAR1 overexpression is associated with cervical cancer progression and angiogenesis. Diagn Pathol 2017;12:12.
195. Song C, Sakurai M, Shiromoto Y, Nishikura K. Functions of the RNA editing enzyme ADAR1 and their relevance to human diseases. Genes (Basel) 2016;7.
196. Zipeto MA, Jiang Q, Melese E, Jamieson CH. RNA rewriting, recoding, and rewiring in human disease. Trends Mol Med 2015;21:549-59.
197. Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, Ablain J, et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science 2016;351:aad2197.
198. Kato S, Lippman SM, Flaherty KT, Kurzrock R. The conundrum of genetic "Drivers" in benign conditions. J Natl Cancer Inst 2016;108: 1-13.
199. Patton EE,Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005;15: 249-54.
200. McNeal AS, Liu K, Nakhate V, Natale CA, Duperret EK, Capell BC, et al. CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discov 2015;5:1072-85.
201. Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7Overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov 2015;5:410-23.
202. Sanchez-Danes A, Hannezo E, Larsimont JC, Liagre M, Youssef KK, Simons BD, et al. Defining the clonal dynamics leading to mouse skin tumour initiation. Nature 2016;536:298-303.
203. Youssef KK, Lapouge G, Bouvree K, Rorive S, Brohee S, Appelstein O, et al. Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat Cell Biol 2012;14:1282-94.
204. Wei D, Wang L, Yan Y, Jia Z, Gagea M, Li Z, et al. KLF4 is essential for induction of cellular identity change and acinar-to-ductal reprogramming during early pancreatic carcinogenesis. Cancer Cell 2016;29: 324-38.
205. Liu X, Pitarresi JR, Cuitino MC, Kladney RD, Woelke SA, Sizemore GM, et al. Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. Genes Dev 2016;30: 1943-55.
206. Willimsky G1, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008;205:1687-700.
207. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 2014;146:1784-94.
208. Munoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol 2016;16:741-750.
209. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 2014;6: 221ra13.
210. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, MatsumotoM,Nagano S, et al. Aberrant PD-L1 expression through 30-UTR disruption in multiple cancers. Nature 2016;534:402-6.
211. Mitra A, MacIntyre DA, Marchesi JR, Lee YS, Bennett PR, Kyrgiou M. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome 2016;4:58.
212. Tuna M, Amos CI. Next generation sequencing and its applications in HPV-Associated cancers. Oncotarget 2017;8:8877-89.
213. Iheagwara UK, Beatty PL, Van PT, Ross TM, Minden JS, Finn OJ. Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-Associated antigens: a new view of cancer immunosurveillance. Cancer Immunol Res 2014;2:263-73.
214. Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 2015;126:2475-8.
215. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017;355:eaaf8399.
216. Rashidian M, Keliher EJ, Bilate AM, Duarte JN, Wojtkiewicz GR, Jacobsen JT, et al. Noninvasive imaging of immune responses. Proc Natl Acad Sci U S A 2015;112:6146-51.
217. Cuccarese MF, Dubach JM, Pfirschke C, Engblom C, Garris C, Miller MA, et al. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat Commun 2017;8:14293.
218. Serrao EM, KettunenMI, Rodrigues TB, Dzien P, Wright AJ, Gopinathan A, et al. MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. Gut 2016;65:465-75.
219. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res 2013;6:18-26.
220. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 2015;112:1809-14.
221. Incio J, Suboj P, Chin SM, Vardam-Kaur T, Liu H, Hato T, et al. Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-Associated macrophages. PLoS One 2015;10: e0141392.
222. Cuyas E, Fernandez-Arroyo S, Joven J, Menendez JA. Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle 2016;15: 3355-61.
223. Cao Y, Nishihara R, Qian ZR, Song M, Mima K, Inamura K, et al. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology 2016; 151:879-92.
224. McLean MH, Murray GI, Stewart KN, Norrie G, Mayer C, Hold GL, et al. The inflammatory microenvironment in colorectal neoplasia. PLoS One 2011;6:e15366.
225. Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome 2016;4:69.
226. Robles AI, Traverso G, Zhang M, Roberts NJ, Khan MA, Joseph C, et al. Whole-exome sequencing analyses of inflammatory bowel disease-Associated colorectal cancers. Gastroenterology 2016;150: 931-43.
227. Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, et al. Genomic alterations observed in colitis-Associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology 2016;151:278-87.
228. Chudnovskiy A, Mortha A, Kana V, Kennard A, Ramirez JD, Rahman A, et al. Host-protozoan interactions protect from mucosal infections through activation of the inflammasome. Cell 2016;167:444-56.
229. Filyk HA, Osborne LC. The multibiome: the intestinal ecosystem's influence on immune homeostasis, health, and disease. EBioMedicine 2016; 13:46-54.
230. Nowarski R, Jackson R, Gagliani N, de Zoete MR, Palm NW, Bailis W, et al. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell 2015;163:1444-56.
231. Earle KA, Billings G, Sigal M, Lichtman JS, Hansson GC, Elias JE, et al. Quantitative imaging of gut microbiota spatial organization. Cell Host Microbe 2015;18:478-88.
232. Komaroff AL. The microbiome and risk for obesity and diabetes. JAMA 2017;317:355-6.
233. Johnson CH, Spilker ME, Goetz L, Peterson SN, Siuzdak G. Metabolite and microbiome interplay in cancer immunotherapy. Cancer Res 2016; 76:6146-52.
234. Rooks MG, Garrett WS. Gutmicrobiota, metabolites and host immunity. Nat Rev Immunol 2016;16:341-52.
235. Bouslimani A, Porto C, Rath CM, Wang M, Guo Y, Gonzalez A, et al. Molecular cartography of the human skin surface in 3D. Proc Natl Acad Sci U S A 2015;112:E2120-9.
236. Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest 2017;127:106-16.
237. Koeppel M, Garcia-Alcalde F, Glowinski F, Schlaermann P, Meyer TF. Helicobacter pylori infection causes characteristic DNA damage patterns in human cells. Cell Rep 2015;11:1703-13.
238. Lennard KS, Goosen RW, Blackburn JM. Bacterially-Associated transcriptional remodelling in a distinct genomic subtype of colorectal cancer provides a plausible molecular basis for disease development. PLoS One 2016;11:e0166282.
239. Thiele Orberg E, Fan H, Tam AJ, Dejea CM, Destefano Shields CE, Wu S, et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol 2016;10:421-33.
240. Bressa C, Bailen-Andrino M, Perez-Santiago J, Gonzalez-Soltero R, Perez M, Montalvo-Lominchar MG, et al. Differences in gut microbiota profile between women with active lifestyle and sedentary women. PLoS One 2017;12:e0171352.
241. O'Keefe SJ, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun 2015;6:6342.
242. Grigg JB, Sonnenberg GF. Host-Microbiota interactions shape local and systemic inflammatory diseases. J Immunol 2017;198:564-71.
243. Mehta RS, Nishihara R, Cao Y, Song M, Mima K, Qian ZR, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue. JAMA Oncol 2017 Jan 26:[Epub ahead of print].
244. Beyaz S, Mana MD, Roper J, Kedrin D, Saadatpour A, Hong SJ, et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature 2016;531:53-8.
245. Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, et al. Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity. Cancer Discov 2017;Feb 15:[Epub ahead of print].
246. Gall A, Fero J, McCoy C, Claywell BC, Sanchez CA, Blount PL, et al. Bacterial composition of the human upper gastrointestinal tract microbiome is dynamic and associated with genomic instability in a Barrett's esophagus cohort. PLoS One 2015;10:e0129055.
247. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153:17-37.
248. Bassani-Sternberg M, Braunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016;7:13404.
249. Olsen L, Johan Kudahl U, Winther O, Brusic V. Literature classification for semi-Automated updating of biological knowledgebases. BMC Genomics 2013;14:S14.
250. Backert L, Kohlbacher O. Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med 2015;7:119.
251. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 2007;8:424.
252. Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 2015;125:3413-21.
253. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014;124:453-62.
254. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
255. Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, et al. Targeting of cancer neoantigenswith donor-derived T cell receptor repertoires. Science 2016;352:1337-41.
256. Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014;211: 2231-48.
257. Srivastava PK. Neoepitopes of cancers: Looking back, looking ahead. Cancer Immunol Res 2015;3:969-77.
258. Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE. Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine 2017;35: 1094-100.
259. Welter D,MacArthur J,Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014;42:D1001-6.
260. Engin HB, Kreisberg JF, Carter H. Structure-based analysis reveals cancer missense mutations target protein interaction interfaces. PLoS One 2016;11:e0152929.
261. Wang D, Quan Y, Yan Q, Morales JE,Wetsel RA. Targeted disruption of the beta2-microglobulin gene minimizes the immunogenicity of human embryonic stem cells. Stem Cells Transl Med 2015;4:1234-45.
262. Echterdiek F, Janikovits J, Staffa L, Muller M, Lahrmann B, Fruhschutz M, et al. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-Associated colorectal cancer. Oncoimmunology 2016;5:e1075692.
263. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819-29.
264. Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017 Feb 24:[Epub ahead of print].
265. Piunti A, Shilatifard A. Epigenetic balance of gene expression by Polycomb and COMPASS families. Science 2016;352:aad9780.
266. Lin C, Garruss AS, Luo Z, Guo F, Shilatifard A. The RNAPol II elongation factor Ell3marks enhancers in ES cells and primes future gene activation. Cell 2013;152:144-56.
267. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem 2012;81:65-95.
268. Hu D, Gao X, Cao K, Morgan MA, Mas G, Smith ER, et al. Not all H3K4 methylations are created equal: Mll2/COMPASS dependency in primordial germ cell specification. Mol Cell 2017;65: 460-75.
269. Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev 2011;25:661-72.
270. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010;37:429-37.
271. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010;10:721-8
272. Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, et al. ASH1L links histone H3 Lysine 36 Dimethylation to MLL Leukemia. Cancer Discov 2016;6:770-83.
273. Christofides A, Karantanos T, Bardhan K, Boussiotis VA. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget 2016;7:85624-40.
274. Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, et al. Oncogenic Deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discov 2016;6:1006-21.
275. Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med 2016;22: 128-34.
276. Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia 2014;28:44-9.
277. Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med 2016;213:1479-96.
278. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013; 45:592-601.
279. Tordella L, Khan S, Hohmeyer A, Banito A, Klotz S, Raguz S, et al. SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer. Genes Dev 2016;30:2187-98.
280. Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet 2017;49:296-302.
281. Kartha N, Shen L, Maskin C, Wallace M, Schimenti JC. The chromatin remodeling component arid1a is a suppressor of spontaneousmammary tumors in mice. Genetics 2016;203:1601-11.
282. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
283. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
284. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012;483:484-8.
285. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27:836-52.
286. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17-30.
287. Koeffler HP, Leong G. Preleukemia: one name, many meanings. Leukemia 2017;31:534-42.
288. Schuyler RP, Merkel A, Raineri E, Altucci L, Vellenga E, Martens JH, et al. Distinct trends ofDNAmethylation patterning in the Innate and Adaptive Immune Systems. Cell Rep 2016;17:2101-11.
289. Dimitrova E, Turberfield AH, Klose RJ. Histone demethylases in chromatin biology and beyond. EMBO Rep 2015;16:1620-39.
290. Mazor T, Pankov A, Song JS, Costello JF. Intratumoral Heterogeneity of the Epigenome. Cancer Cell 2016;29:440-51.
291. Grün D, Muraro MJ, Boisset JC, Wiebrands K, Lyubimova A, Dharmadhikari G, et al. De novo prediction of stem cell identity using single-cell transcriptome data. Cell Stem Cell 2016;19: 266-77.
292. Stegle O, Teichmann SA, Marioni JC. Computational and analytical challenges in single-cell transcriptomics. Nat Rev Genet 2015; 16:133-45.
293. Mahata B, Zhang X, Kolodziejczyk AA, Proserpio V, Haim-Vilmovsky L, Taylor AE, et al. Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis. Cell Rep 2014;7:1130-42.
294. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
295. Navin NE. Cancer genomics: one cell at a time. Genome Biol 2014; 15:452.
296. Almendro V, Kim HJ, Cheng YK, Gonen M, Itzkovitz S, Argani P, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014;74:1338-48.
297. Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010;120:636-44.
298. Grundberg I, Kiflemariam S, Mignardi M, Imgenberg-Kreuz J, Edlund K, Micke P, et al. In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. Oncotarget 2013;4: 2407-18.
299. Ikeda S, Takabe K, Inagaki M, Funakoshi N, Suzuki K. Detection of gene point mutation in paraffin sections using in situ loop-mediated isothermal amplification. Pathol Int 2007;57:594-9.
300. Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet 2015;47:1212-9.
301. Martinez P, Timmer MR, Lau CT, Calpe S, Sancho-Serra Mdel C, Straub D, et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun 2016;7: 12158.
302. Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X, et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012;148:873-85.
303. Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAKSTAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015;5:316-31.
304. Gawad C, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc Natl Acad Sci U S A 2014;111:17947-52.
305. Stahl PL, Salmen F, Vickovic S, Lundmark A, Navarro JF,Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science 2016;353:78-82.
306. Sheng K, Cao W, Niu Y, Deng Q, Zong C. Effective detection of variation in single-cell transcriptomes using MATQ-seq. Nat Methods 2017; 14:267-270.
307. Rotem A, Ram O, Shoresh N, Sperling RA, Goren A, Weitz DA, et al. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat Biotechnol 2015;33:1165-72.
308. Cleary B, Brito IL, Huang K, Gevers D, Shea T, Young S, et al. Detection of low-Abundance bacterial strains in metagenomic datasets by eigengenome partitioning. Nat Biotechnol 2015;33:1053-60.
309. Geva-Zatorsky N, Alvarez D, Hudak JE, Reading NC, Erturk-Hasdemir D, Dasgupta S, et al. In vivo imaging and tracking of host-microbiota interactions via metabolic labeling of gut anaerobic bacteria. Nat Med 2015;21:1091-100.
310. Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
311. Grun D, van Oudenaarden A. Design and analysis of single-cell sequencing experiments. Cell 2015;163:799-810.
312. Macaulay IC, Voet T. Single cell genomics: advances and future perspectives. PLoS Genet 2014;10:e1004126.
313. Chen X, Love JC, Navin NE, Pachter L, Stubbington MJ, Svensson V, et al. Single-cell analysis at the threshold. Nat Biotechnol 2016;34: 1111-18.
314. Nestorowa S, Hamey FK, Pijuan Sala B, Diamanti E, Shepherd M, Laurenti E, et al. A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. Blood 2016;128:e20-31.
315. Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells frommetastatic breast cancer patients. Mol Oncol 2015;9:749-57.
316. Stephens ZD, Lee SY, Faghri F, Campbell RH, Zhai C, Efron MJ, et al. Big data: Astronomical or Genomical? PLoS Biol 2015;13:e1002195.
317. Bock C, Farlik M, Sheffield NC. Multi-Omics of single cells: strategies and applications. Trends Biotechnol 2016;34:605-8.
318. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014; 4:650-61.
319. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
320. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra54.
321. Nair N, Camacho-Vanegas O, Rykunov D, Dashkoff M, Camacho SC, Schumacher CA, et al. Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study. PLoS Med 2016;13:e1002206.
322. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, et al.Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 2015;6:7686.
323. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016; 8:346ra92.
324. Birkenkamp-Demtroder K, Nordentoft I, Christensen E,Hoyer S, Reinert T, Vang S, et al.Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 2016;70:75-82.
325. Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun 2015;6:8258.
326. Guerrero-Preston R, Valle BL, Jedlicka A, Turaga N, Folawiyo O, Pirini F, et al. Molecular triage of premalignant lesions in liquid-based cervical cytology and circulating cell-free dna from urine, using a panel of methylated human papilloma virus and host genes. Cancer Prev Res 2016;9:915-24.
327. Fernandez-Cuesta L, Perdomo S, Avogbe PH, Leblay N, Delhomme TM, Gaborieau V, et al. Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. EBioMedicine 2016; 10:117-23.
328. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 2016;34:547-55.
329. Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 2016;7:48832-41.
330. Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci 2015;2:13.
331. Wen L, Li J, Guo H, Liu X, Zheng S, Zhang D, et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. Cell Res 2015;25:1250-64.
332. Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 2015;28:666-76.
333. Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 2014;9:e111597.
334. Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 2015;373:243-51.
335. Perez-Rogers JF, Gerrein J, Anderlind C, Liu G, Zhang S, Alekseyev Y, et al. Shared gene expression alterations in nasal and bronchial epithelium for lung cancer detection. J Natl Cancer Inst 2017 in press.
336. Pantel K. Blood-based analysis of circulating cell-free DNA and tumor cells for early cancer detection. PLoS Med 2016;13:e1002205.
337. Gorges TM, Kuske A, Rock K, Mauermann O, Muller V, Peine S, et al. Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clin Chem 2016;62:1504-15.
338. Tsay JC, Li Z, Yie TA, Wu F, Segal L, Greenberg AK, et al. Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma. PLoS One 2015;10:e0118132.
339. Pipinikas CP, Kiropoulos TS, Teixeira VH, Brown JM, Varanou A, Falzon M, et al. Cell migration leads to spatially distinct but clonally related airway cancer precursors. Thorax 2014;69:548-57.
340. Koper A, Zeef LA, Joseph L, Kerr K, Gosney J, Lindsay MA, et al. Whole transcriptome analysis of pre-invasive and invasive early squamous lung carcinoma in archival laser microdissected samples. Respir Res 2017;18:12.
341. Jeong Y, Hoang NT, Lovejoy A, Stehr H, Newman AM, Gentles AJ, et al. Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov 2017; 7:86-101.
342. Fitzgerald DM, Hastings PJ, Rosenberg SM. Stress-induced mutagenesis: implications in cancer and drug resistance. Ann Rev Cancer Biol 2017;1:6.1-6.22.
343. Li X, Paulson TG, Galipeau PC, Sanchez CA, Liu K, Kuhner MK, et al. Assessment of esophageal adenocarcinoma risk using somatic chromosome alterations in longitudinal samples in Barrett's esophagus. Cancer Prev Res 2015;8:845-56.
344. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-98.
345. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Agerelated mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014;20:1472-8.
346. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B,Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-506.
347. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015;126:9-16.
348. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-Associated mutations is ubiquitous in healthy adults. Nat Commun 2016;7:12484.
349. Park CY (ed.). Hematopoiesis in Aging. Semin Hematol 2016;54;1-56.
350. Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, et al. Stagespecific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell Stem Cell 2017;20:315-28.
351. Matatall KA, Jeong M, Chen S, Sun D, Chen F, Mo Q, et al. Chronic infection depletes hematopoietic stem cells through stress-induced terminal differentiation. Cell Rep 2016;17:2584-95.
352. Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood 2016;128:337-47.
353. Cargo CA, Rowbotham N, Evans PA, Barrans SL, Bowen DT, Crouch S, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 2015;126:2362-5.
354. Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, et al. DNMT3A Haploinsufficiency Transforms FLT3ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia. Cancer Discov 2016;6:501-15.
355. Lubking A, Vosberg S, Konstandin NP, Dufour A, Graf A, Krebs S, et al. Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation. Leuk Res Rep 2015;4:72-5.
356. Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 2016;128:1121-8.
357. Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 2015;126:2484-90.
358. Parikh SA, Kay NE, Shanafelt TD. Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. Clin Adv Hematol Oncol 2013;11:720-9.
359. Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood 2011; 117:1911-6.
360. Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia 2014;28:2395-8.
361. Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015;526:519-24.
362. Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortum KM, et al. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia 2017;31:170-76.
363. Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol 2010; 151:152-8.
364. Oddsson A, Kristinsson SY, Helgason H, Gudbjartsson DF, Masson G, Sigurdsson A, et al. The germline sequence variant rs2736100-C in TERT associates with myeloproliferative neoplasms. Leukemia 2014; 28:1371-4.
365. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015;526:525-30.
366. Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, et al. Infectious complications among individuals with clinical monoclonal Bcell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia 2013;27:136-41.
367. Solomon BM, Chaffee KG, Moreira J, Schwager SM, Cerhan JR, Call TG, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 2016;30:331-6.
368. Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol 2009;147:444-9.
369. Slager SL. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukemia. Nat Commun 2017; 141:14175.
370. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37.
371. Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW,Call TG, et al. Longterm repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 2013;121:4137-41.
372. Henry CJ, Casas-Selves M, Kim J, Zaberezhnyy V, Aghili L, Daniel AE, et al. Aging-Associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. J Clin Invest 2015;125: 4666-80.
373. Martin-Lorenzo A, Hauer J, Vicente-Duenas C, Auer F,Gonzalez-Herrero I, Garcia-Ramirez I, et al. Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility. Cancer Discov 2015;5:1328-43.
374. Ganapathi KA, Pittaluga S, Odejide OO, Freedman AS, Jaffe ES. Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica 2014;99:1421-32.
375. Cowan G, Weston-Bell NJ, Bryant D, Seckinger A, Hose D, Zojer N, et al. Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma. Oncotarget 2015; 6:13229-40.
376. Agirre X, CastellanoG, Pascual M, Heath S, Kulis M, Segura V, et al. Wholeepigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res 2015;25:478-87.
377. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128:2599-606.
378. Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, et al. Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood Cancer J 2017;7:e537.
379. Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, PuigN, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood 2016;127:3035-9.
380. Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, et al. Microenvironment-dependent growth of pre-neoplastic and malignant plasma cells in humanized mice. Nat Med 2016;22:1351-7.
381. Weinhold N, Johnson DC, Rawstron AC, Forsti A, Doughty C, Vijayakrishnan J, et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood 2014;123:2513-7.
382. Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med 2016;374:555-61.
383. Pavlova EV, Archer J, Wang S, Dekker N, Aerts JM, Karlsson S, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-Associated B-cell malignancy. J Pathol 2015;235:113-24.
384. Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, et al. Transforming cancer prevention through precision medicine and immuneoncology. Cancer Prev Res 2016;9:2-10.
385. Sedic M, Kuperwasser C. BRCA1-hapoinsufficiency: unraveling the molecular and cellular basis for tissue-specific cancer. Cell Cycle 2016; 15:621-7.
386. Bauman JE, Grandis J. Oral Cancer Chemoprevention-The End of EPOC, the Beginning of an Epoch of Molecular Selection. JAMA Oncol 2016;2:178-9.
387. WilliamWNJr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, et al. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol 2016; 2:209-16.
388. William WN Jr, Uraoka N, Peng SA, Lee JJ, El-Naggar AK, Parra E, et al. Abstract 387: Immune profiling of oral pre-malignant lesions (OPLs): an Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis. J Clin Oncol/ASCO 2017.
389. Lam S,Mandrekar SJ,Gesthalter Y, Allen Ziegler KL, Seisler DK, Midthun DE, et al. A randomized phase IIb trial of myo-inositol in smokers with bronchial dysplasia. Cancer Prev Res 2016;9:906-14.
390. Zumwalt TJ, Wodarz D, Komarova NL, Toden S, Turner J, Cardenas J, et al. Aspirin-induced chemoprevention and response kinetics are enhanced by PIK3CA mutations in colorectal cancer cells. Cancer Prev Res 2017; 10:208-18.
391. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016;16:173-86.
392. KettnerNM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, et al. Circadian homeostasis of liver metabolismsuppresses hepatocarcinogenesis. Cancer Cell 2016;30:909-24.
393. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385: 956-65.
394. Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, et al. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol 2017;2:23-31.
395. Emmons KM, Colditz GA. Realizing the potential of cancer prevention-the role of implementation science. N Engl J Med 2017;376:986-90.
396. Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res 2017;231:21-33.
397. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 2017;9:eaah3560.
398. Ho TT, Warr MR, Adelman ER, Lansinger OM, Flach J, Verovskaya EV, et al. Autophagy maintains the metabolism and function of young and old stem cells. Nature 2017;543:205-10.
399. Corriden R, Hollands A, Olson J, Derieux J, Lopez J, Chang JT, et al. Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide. Nat Commun 2015; 6:8369.
400. Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Garrido-Martin D, et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell 2016;167:1398-414.
401. Ecker S, Chen L, Pancaldi V, Bagger FO, Fernandez JM, Carrillo de Santa Pau E, et al. Genome-wide analysis of differential transcriptional and epigenetic variability across human immune cell types. Genome Biol 2017;18:18.
402. Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR, Emond MJ, et al. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A 2016;113:6005-10.
403. Abbosh C, Venkatesan S, Janes SM, Fitzgerald RC, Swanton C. Evolutionary dynamics in pre-invasive neoplasia. Curr Opin Syst Biol 2017 Feb 16:[Epub ahead of print].
404. Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, et al. Uninterrupted sedentary behavior downregulates BRCA1 gene expression. Cancer Prev Res 2016;9:83-8.
405. Tanay A, Regev A. Scaling single-cell genomics from phenomenology to mechanism. Nature 2017;541:331-8.
406. Drost J, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 2015;521:43-7.
407. Keysselt K, Kreutzmann T, Rother K, Kerner C, Krohn K, Przybilla J, et al. Different in vivo and in vitro transformation of intestinal stem cells in mismatch repair deficiency. Oncogene 2016 Dec 12:[Epub ahead of print].
408. Zhang Z, Christin JR, Wang C, Ge K, OktayMH, Guo W. Mammary-stemcell-based somatic mousemodels reveal breast cancer drivers causing cell fate dysregulation. Cell Rep 2016;16:3146-56.
409. Gundry MC, Brunetti L, Lin A, Mayle AE, Kitano A, Wagner D, et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. Cell Rep 2016;17:1453-61.
410. Papapetrou EP. Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat Med 2016;22: 1392-401.
411. Zumwalde NA, Haag JD, Sharma D, Mirrielees JA, Wilke LG, Gould MN, et al. Analysis of immune cells from human mammary ductal epithelial organoids reveals Vdelta2+ T cells that efficiently target breast carcinoma cells in the presence of bisphosphonate. Cancer Prev Res 2016;9:305-16.
412. Yamamoto Y, Wang X, Bertrand D, Kern F, Zhang T, Duleba M, et al. Mutational spectrum of Barrett's stem cells suggests paths to initiation of a precancerous lesion. Nat Commun 2016;7:10380.